MedPath

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Phase 1
Recruiting
Conditions
Metastatic Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Interventions
Registration Number
NCT06483334
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
98
Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

  • Must have histologically documented, locally advanced/metastatic urothelial carcinoma (la/mUC).
  • Must provide an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion demonstrating UC, not previously irradiated, and adequate for biomarker evaluation. A newly obtained biopsy is strongly preferred, but not required if archival tissue is evaluable.
  • Any AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Endocrine-related AEs adequately treated with hormone replacement are eligible.
  • PART 1 ONLY: Participants must have received platinum-based chemotherapy for treatment of la/mUC.
  • PART 1 ONLY: Participants must not have received >2 lines of therapy for la/mUC. Platinum-based chemotherapy followed by avelumab maintenance is considered 2 lines of therapy.
  • PART 2 ONLY: Participants must not have received prior systemic therapy for la/mUC.
Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Known additional malignancy that is progressing or has required active treatment within the past 3 years.
  • Known active central nervous system metastases and/or carcinomatous meningitis.
  • Has Grade ≥2 peripheral neuropathy.
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease and/or serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention.
  • Has active keratitis or corneal ulcerations. Superficial punctate keratitis is allowed if the disorder is being adequately treated in the opinion of the investigator.
  • Has a history of uncontrolled diabetes.
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
  • PART 2 ONLY: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention. Inhaled or topical steroids are permitted in the absence of active autoimmune disease. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency.
  • PART 2 ONLY: Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy. - Is human immunodeficiency virus (HIV)-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has active Hepatitis B or Hepatitis C virus infection.
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has an active infection requiring systemic therapy.
  • PART 2 ONLY: History of allogeneic tissue/solid organ transplant.
  • Has not adequately recovered from major surgery or has ongoing surgical complications.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sacituzumab tirumotecan plus EV and pembrolizumabSacituzumab tirumotecanParticipants will receive sacituzumab tirumotecan as an IV infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision. Participants will also receive pembrolizumab 200 mg as an IV infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles).
Sacituzumab tirumotecan plus EV and pembrolizumabPembrolizumabParticipants will receive sacituzumab tirumotecan as an IV infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision. Participants will also receive pembrolizumab 200 mg as an IV infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles).
Sacituzumab tirumotecan plus EVEnfortumab VedotinParticipants will receive sacituzumab tirumotecan as an intravenous (IV) infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
Sacituzumab tirumotecan plus EVSacituzumab tirumotecanParticipants will receive sacituzumab tirumotecan as an intravenous (IV) infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
Sacituzumab tirumotecan plus EV and pembrolizumabEnfortumab VedotinParticipants will receive sacituzumab tirumotecan as an IV infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision. Participants will also receive pembrolizumab 200 mg as an IV infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles).
Primary Outcome Measures
NameTimeMethod
Part 1: Percentage of Participants Who Experienced At Least One Adverse Event (AE)Up to ~3 years

An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants experiencing an AE in Part 1 will be reported.

Part 2: Percentage of Participants with DLTUp to 21 days

A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the NCI CTCAE 5.0. The number of participants who experience a DLT in Part 2 will be reported.

Part 2: Percentage of Participants Who Discontinued Study Treatment Due to an AEUp to ~2 years

An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants who discontinue study treatment due to an AE in Part 2 will be reported.

Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)Up to 21 days

A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT in Part 1 will be reported.

Part 1: Percentage of Participants Who Discontinued Study Treatment Due to an AEUp to ~2 years

An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants who discontinue study treatment due to an AE in Part 1 will be reported.

Part 2: Objective Response Rate (ORR)Up to ~3 years

ORR is defined as the percentage of participants who achieve a confirmed complete response (CR) (disappearance of all target lesions) or partial response (PR) (at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator. ORR will be reported for participants in Part 2.

Part 2: Percentage of Participants Who Experienced At Least One AEUp to ~3 years

An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants experiencing an AE in Part 2 will be reported.

Secondary Outcome Measures
NameTimeMethod
Part 1: Cmax of Free Payload for Sacituzumab TirumotecanDays 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Cmax of free payload for sacituzumab tirumotecan in Part 1.

Part 1: Cmax of Enfortumab Vedotin-ADCDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

Blood samples collected at designated time points will be used to determine the Cmax of enfortumab vedotin-ADC in Part 1.

Part 1: Incidence of ADA to Enfortumab VedotinDay 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4 and 8

Blood samples collected at designated timepoints will be used to determine the ADA response to sacituzumab tirumotecan. The incidence of ADAs over time in Part 1 will be presented.

Part 1: Maximum Serum Concentration (Cmax) of Sacituzumab Tirumotecan-Antibody-Drug Conjugate (ADC)Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Cmax of sacituzumab tirumotecan-ADC in Part 1.

Part 1: Ctrough of Free Payload for Sacituzumab TirumotecanDays 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Ctrough of free payload for sacituzumab tirumotecan in Part 1.

Part 1: Ctrough of Free Payload for Enfortumab VedotinDays 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

Blood samples collected at designated time points will be used to determine the Ctrough of free payload for EV in Part 1.

Part 1: Incidence of Antidrug Antibodies (ADA) to Sacituzumab TirumotecanDay 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated timepoints will be used to determine the ADA response to sacituzumab tirumotecan. The incidence of ADAs over time in Part 1 will be presented.

Part 2: Cmax of Free Payload for Sacituzumab TirumotecanDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Cmax of free payload for sacituzumab tirumotecan in Part 2.

Part 1: ORRUp to ~3 years

ORR is defined as the percentage of participants who achieve a confirmed CR or PR per RECIST 1.1 as assessed by investigator. ORR will be reported for participants in Part 1.

Part 1: Serum Trough Concentration (Ctrough) of Sacituzumab Tirumotecan-ADCDays 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Ctrough of sacituzumab tirumotecan-ADC in Part 1.

Part 2: Cmax of Sacituzumab Tirumotecan-ADCDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Cmax of sacituzumab tirumotecan-ADC in Part 2.

Part 2: Cmax of Free Payload for PembrolizumabDays 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Cmax of free payload for pembrolizumab.

Part 2: Duration of Response (DOR)Up to ~3 years

For participants who demonstrate confirmed CR or PR per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by investigator will be presented.

Part 1: Ctrough of Enfortumab Vedotin-ADCDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

Blood samples collected at designated time points will be used to determine the Ctrough of enfortumab vedotin-ADC in Part 1.

Part 1: Cmax of Free Payload for Enfortumab VedotinDays 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

Blood samples collected at designated time points will be used to determine the Cmax of free payload for EV in Part 1.

Part 2: Ctrough of Sacituzumab Tirumotecan-ADCDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Ctrough of sacituzumab tirumotecan-ADC in Part 2.

Part 2: Cmax of Enfortumab Vedotin-ADCDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

Blood samples collected at designated time points will be used to determine the Cmax of enfortumab vedotin-ADC in Part 2.

Part 2: Ctrough of Enfortumab Vedotin-ADCDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

Blood samples collected at designated time points will be used to determine the Ctrough of enfortumab vedotin-ADC in Part 2.

Part 2: Ctrough of Pembrolizumab-ADCDays 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Ctrough of pembrolizumab-ADC.

Part 2: Ctrough of Free Payload for Sacituzumab TirumotecanDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Ctrough of free payload for sacituzumab tirumotecan in Part 2.

Part 2: Ctrough of Free Payload for PembrolizumabDays 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Ctrough of free payload for pembrolizumab.

Part 2: Incidence of ADA to Enfortumab VedotinDay 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8

Blood samples collected at designated timepoints will be used to determine the ADA response to EV. The incidence of ADAs over time in Part 2 will be presented.

Part 2: Cmax of Free Payload for Enfortumab VedotinDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

Blood samples collected at designated time points will be used to determine the Cmax of free payload for EV in Part 2.

Part 2: Ctrough of Free Payload for Enfortumab VedotinDays 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

Blood samples collected at designated time points will be used to determine the Ctrough of free payload for EV in Part 2.

Part 2: Cmax of Pembrolizumab-ADCDays 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated time points will be used to determine the Cmax of pembrolizumab-ADC.

Part 2: Incidence of ADA to PembrolizumabDay 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated timepoints will be used to determine the ADA response to pembrolizumab. The incidence of ADAs over time be presented.

Part 2: Incidence of ADA to Sacituzumab TirumotecanDay 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

Blood samples collected at designated timepoints will be used to determine the ADA response to sacituzumab tirumotecan. The incidence of ADAs over time in Part 2 will be presented.

Trial Locations

Locations (23)

Sheba Medical Center-ONCOLOGY ( Site 4503)

🇮🇱

Ramat Gan, Israel

University of California San Francisco HDFCCC ( Site 4044)

🇺🇸

San Francisco, California, United States

Indiana University Melvin and Bren Simon Cancer Center ( Site 4011)

🇺🇸

Indianapolis, Indiana, United States

Dana-Farber Cancer Institute ( Site 4047)

🇺🇸

Boston, Massachusetts, United States

Siteman Cancer Center ( Site 4038)

🇺🇸

Saint Louis, Missouri, United States

Icahn School of Medicine at Mount Sinai ( Site 4018)

🇺🇸

New York, New York, United States

Cleveland Clinic-Taussig Cancer Center ( Site 4036)

🇺🇸

Cleveland, Ohio, United States

Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 4041)

🇺🇸

Salt Lake City, Utah, United States

The Ottawa Hospital - General Campus ( Site 4105)

🇨🇦

Ottawa, Ontario, Canada

Princess Margaret Cancer Centre ( Site 4106)

🇨🇦

Toronto, Ontario, Canada

Centre Hospitalier Lyon Sud ( Site 4606)

🇫🇷

Pierre-Benite, Rhone-Alpes, France

Rambam Health Care Campus ( Site 4501)

🇮🇱

Haifa, Israel

Rabin Medical Center-Oncology ( Site 4504)

🇮🇱

Petah Tikva, Israel

Ospedale San Raffaele-Oncologia Medica ( Site 4403)

🇮🇹

Milano, Lombardia, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 4405)

🇮🇹

Milano, Italy

Severance Hospital, Yonsei University Health System-Medical oncology ( Site 4903)

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center-Department of Oncology ( Site 4901)

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center ( Site 4902)

🇰🇷

Seoul, Korea, Republic of

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 4302)

🇳🇱

Amsterdam, Noord-Holland, Netherlands

Hospital Universitari Vall d'Hebron-Oncology ( Site 4767)

🇪🇸

Barcelona, Spain

Hospital Clinico San Carlos ( Site 4765)

🇪🇸

Madrid, Spain

National Cheng Kung University Hospital-Clinical Trial Center ( Site 4803)

🇨🇳

Tainan, Taiwan

St Bartholomew s Hospital ( Site 4206)

🇬🇧

London, London, City Of, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath